Clinical Trial Update: An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease [Phase 3]

View source ↗

Summary

A Phase 3 efficacy and safety trial evaluating GNR-086 (canakinumab biosimilar) versus Ilaris (canakinumab) in adults with adult-onset Still's disease has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adult-onset Still Disease

Drugs mentioned

• GNR-086
• ILARIS (canakinumab)

Snippet

Sponsor: AO GENERIUM | Conditions: Still's Disease Adult Onset | Phase 3 | Status: COMPLETED